Aliases & Classifications for Glioblastoma Multiforme

MalaCards integrated aliases for Glioblastoma Multiforme:

Name: Glioblastoma Multiforme 12 72 51 14 69
Glioblastoma 41 69
Grade Iv Adult Astrocytic Tumor 12
Primary Glioblastoma Multiforme 12
Adult Glioblastoma Multiforme 12
Spongioblastoma Multiforme 12
Primary Glioblastoma 69
Adult Glioblastoma 69
Gbm 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3068
MeSH 41 D005909

Summaries for Glioblastoma Multiforme

Disease Ontology : 12 An astrocytoma characterized by the presence of small areas of necrotizing tissue that is surrounded by anaplastic cells as well as the presence of hyperplastic blood vessels, and that has material basis in abnormally proliferating cells derives from multiple cell types including astrocytes and oligondroctyes.

MalaCards based summary : Glioblastoma Multiforme, also known as glioblastoma, is related to giant cell glioblastoma and glioblastoma proneural subtype, and has symptoms including seizures and headache. An important gene associated with Glioblastoma Multiforme is PTEN (Phosphatase And Tensin Homolog), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Gliadel Wafer and Temodar have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and endothelial, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 72 Glioblastoma, also known as glioblastoma multiforme (GBM), is the most aggressive cancer that begins... more...

Related Diseases for Glioblastoma Multiforme

Diseases related to Glioblastoma Multiforme via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 280)
# Related Disease Score Top Affiliating Genes
1 giant cell glioblastoma 33.1 BRAF EGFR IDH1 MDM2 MGMT PTEN
2 glioblastoma proneural subtype 32.8 CDK4 CDK6
3 glioblastoma 32.6 AKT3 BRAF CDK2 CDK4 CDK6 CDKN2A
4 astrocytoma 31.5 CDK4 CDKN2A DMBT1 EGF EGFR IDH1
5 gliosarcoma 31.4 CDK4 EGFR IDH1 MGMT PTEN RB1
6 meningioma, familial 31.3 EGF PDGFRB PTEN TP53
7 pleomorphic xanthoastrocytoma 31.2 BRAF IDH1 MGMT TP53
8 glioma 31.2 AKT3 CDK4 CDK6 CDKN2A DMBT1 EGF
9 gliomatosis cerebri 31.0 EGFR IDH1 MDM2 PTEN TP53
10 brain cancer 31.0 DMBT1 EGF EGFR IDH1 MGMT PTEN
11 mixed glioma 30.9 IDH1 PDGFRA TP53
12 small cell carcinoma 30.9 EGFR PDGFRA PTEN TP53
13 pilocytic astrocytoma 30.8 BRAF CDK4 CDKN2A HRAS IDH1 MGMT
14 central nervous system lymphoma 30.8 CDKN2A MGMT TP53
15 malignant glioma 30.7 CDK4 CDKN2A DMBT1 EGF EGFR MDM2
16 leiomyosarcoma 30.7 CDK4 MDM2 PDGFRA PDGFRB TP53
17 sarcoma 30.7 BRAF HRAS MDM2 RB1 TP53
18 oligodendroglioma 30.6 CDKN2A EGFR IDH1 MGMT PDGFRA PTEN
19 melanoma 30.6 AKT3 BRAF CDK4 CDK6 CDKN2A GPNMB
20 adenocarcinoma 30.5 BRAF CDKN2A EGF EGFR HRAS PDGFRB
21 thyroid cancer 30.5 BRAF EGF HRAS PTEN TP53
22 prostate cancer 30.0 AKT3 CDK2 CDK4 EGF EGFR HRAS
23 breast cancer 30.0 CDK2 CDK4 CDK6 EGF EGFR HRAS
24 brain glioblastoma multiforme 12.4
25 adult spinal cord glioblastoma multiforme 12.2
26 glioma susceptibility 1 12.2
27 goodpasture syndrome 12.0
28 mismatch repair cancer syndrome 11.5
29 glioma susceptibility 2 11.1
30 glioma susceptibility 3 11.1
31 glioma susceptibility 9 11.1
32 glioblastoma classical subtype 11.1
33 glioblastoma mesenchymal subtype 11.1
34 glioblastoma neural subtype 11.1
35 squamous cell carcinoma of the larynx 10.8 CDKN2A EGFR TP53
36 ring chromosome 7 10.8 CDK4 MDM2 TP53
37 bladder squamous cell carcinoma 10.8 CDKN2A PTEN TP53
38 fibrillary astrocytoma 10.8 IDH1 MGMT TP53
39 cervical adenosquamous carcinoma 10.8 CDKN2A EGFR PDGFRA
40 oropharynx cancer 10.8 CDKN2A EGFR TP53
41 soft tissue sarcoma 10.8 EGFR MDM2 TP53
42 infiltrating angiolipoma 10.8 CDK4 CDKN2A MDM2
43 spinal cord astrocytoma 10.8 IDH1 MGMT TP53
44 basaloid squamous cell carcinoma 10.8 CDKN2A EGFR TP53
45 vulvar seborrheic keratosis 10.8 CDKN2A MTOR
46 tumor suppressor gene on chromosome 11 10.8 BRAF EGFR PTEN
47 endometrial adenocarcinoma 10.8 CDKN2A EGFR PTEN TP53
48 ischemic fasciitis 10.8 CDK4 CDKN2A MDM2
49 anaplastic oligodendroglioma 10.8 CDKN2A EGFR IDH1 MGMT
50 atypical lipomatous tumor 10.8 CDK4 CDKN2A MDM2

Graphical network of the top 20 diseases related to Glioblastoma Multiforme:



Diseases related to Glioblastoma Multiforme

Symptoms & Phenotypes for Glioblastoma Multiforme

UMLS symptoms related to Glioblastoma Multiforme:


seizures, headache

GenomeRNAi Phenotypes related to Glioblastoma Multiforme according to GeneCards Suite gene sharing:

25 (show all 24)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 11.1 HRAS MTOR BRAF EGFR
2 Decreased viability GR00173-A 11.1 PDGFRA
3 Decreased viability GR00221-A-1 11.1 HRAS MTOR EGFR CDK6 AKT3 CDKN2A
4 Decreased viability GR00221-A-2 11.1 HRAS CDK2 CDK6 AKT3
5 Decreased viability GR00221-A-3 11.1 HRAS PDGFRB CDK2 AKT3 CDKN2A PDGFRA
6 Decreased viability GR00221-A-4 11.1 MTOR BRAF EGFR CDK6 AKT3 CDKN2A
7 Decreased viability GR00301-A 11.1 BRAF CDK2 CDK6 AKT3
8 Decreased viability GR00342-S-1 11.1 MTOR PDGFRB
9 Decreased viability GR00342-S-2 11.1 MTOR
10 Decreased viability GR00381-A-1 11.1 BRAF
11 Decreased substrate adherent cell growth GR00193-A-1 10.59 CDK2 CDK6
12 Decreased substrate adherent cell growth GR00193-A-2 10.59 AKT3 CDK2 CDK4 CDK6 EGFR MTOR
13 Decreased substrate adherent cell growth GR00193-A-3 10.59 AKT3 BRAF CDK2 CDK4
14 Decreased substrate adherent cell growth GR00193-A-4 10.59 BRAF CDK2 CDK4
15 Decreased viability in esophageal squamous lineage GR00235-A 10.03 HRAS IDH1 PDGFRA PDGFRB PTEN RB1
16 Decreased cell migration GR00055-A-1 10.02 AKT3 BRAF CDK4 EGFR HRAS MTOR
17 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.98 AKT3 CDK4 EGFR HRAS MTOR PDGFRB
18 Decreased Hepatitis C Virus pseudoparticles (HCVpp GR00234-A-1 9.71 BRAF CDK2 CDK4 EGFR
19 Decreased cella89culturea89derived Hepatitis C virus (HCVcc GR00234-A-2 9.63 BRAF CDK4 EGFR
20 Decreased viability with paclitaxel GR00179-A-1 9.55 EGFR MTOR
21 Decreased viability with paclitaxel GR00179-A-2 9.55 MTOR
22 Decreased viability with paclitaxel GR00179-A-3 9.55 EGFR MTOR
23 Increased cell death HMECs cells GR00103-A-0 9.43 CDK2 EGFR MDM2 PDGFRB PTEN TP53
24 Increased cell viability after pRB stimulation GR00230-A-1 9.02 AKT3 CDK2 CDK4 EGFR PDGFRB

MGI Mouse Phenotypes related to Glioblastoma Multiforme:

43 (show all 27)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.52 AKT3 BRAF CDK2 CDK4 CDK6 CDKN2A
2 homeostasis/metabolism MP:0005376 10.52 MGMT MTOR PDGFRA PDGFRB PTEN RB1
3 growth/size/body region MP:0005378 10.51 RB1 TP53 AKT3 BRAF CDK2 CDK4
4 immune system MP:0005387 10.51 EGFR GPNMB IDH1 MDM2 MTOR PDGFRA
5 cardiovascular system MP:0005385 10.5 EGFR HRAS MDM2 MTOR PDGFRA PDGFRB
6 cellular MP:0005384 10.49 AKT3 BRAF CDK2 CDK4 CDK6 CDKN2A
7 hematopoietic system MP:0005397 10.48 AKT3 BRAF CDK2 CDK4 CDK6 CDKN2A
8 mortality/aging MP:0010768 10.46 CDK4 CDK6 CDKN2A DMBT1 EGFR HRAS
9 behavior/neurological MP:0005386 10.44 TP53 AKT3 BRAF CDK4 CDKN2A GPNMB
10 embryo MP:0005380 10.44 BRAF CDK2 CDK4 CDK6 CDKN2A DMBT1
11 digestive/alimentary MP:0005381 10.42 MDM2 PDGFRA PDGFRB PTEN RB1 TP53
12 neoplasm MP:0002006 10.38 PDGFRA PTEN RB1 TP53 AKT3 BRAF
13 integument MP:0010771 10.36 BRAF CDK2 CDK4 CDKN2A EGF EGFR
14 muscle MP:0005369 10.31 PDGFRA PDGFRB PTEN RB1 TP53 BRAF
15 nervous system MP:0003631 10.3 AKT3 BRAF CDK4 CDKN2A EGFR GPNMB
16 liver/biliary system MP:0005370 10.22 RB1 TP53 BRAF CDK2 CDK4 CDK6
17 normal MP:0002873 10.22 AKT3 BRAF CDK4 EGF EGFR HRAS
18 craniofacial MP:0005382 10.21 BRAF EGFR HRAS MDM2 PDGFRA PDGFRB
19 adipose tissue MP:0005375 10.18 BRAF EGFR MTOR PDGFRB PTEN RB1
20 renal/urinary system MP:0005367 10.1 BRAF CDK4 DMBT1 EGFR HRAS MDM2
21 reproductive system MP:0005389 10.1 BRAF CDK2 CDK4 CDK6 CDKN2A EGF
22 no phenotypic analysis MP:0003012 10.09 CDKN2A EGFR HRAS MDM2 MGMT MTOR
23 limbs/digits/tail MP:0005371 10.08 PDGFRB PTEN RB1 TP53 EGFR MDM2
24 pigmentation MP:0001186 10.07 MDM2 PDGFRA PTEN RB1 TP53 BRAF
25 respiratory system MP:0005388 9.9 BRAF CDKN2A EGFR HRAS IDH1 MGMT
26 skeleton MP:0005390 9.73 BRAF CDKN2A EGFR HRAS IDH1 MDM2
27 vision/eye MP:0005391 9.36 CDKN2A EGF EGFR GPNMB PDGFRB PTEN

Drugs & Therapeutics for Glioblastoma Multiforme

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Gliadel Wafer 17 45 CARMUSTINE Rhone-Poulenc Rorer, Guilford Pharmaceuticals February 1997
2
Temodar 17 45 TEMOZOLOMIDE Schering-Plough August 1999
3
Avastin 17 45 BEVACIZUMAB Genentech July 2009

Drugs for Glioblastoma Multiforme (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 581)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 4342-03-4 5351166
2
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
3
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
4 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2
5 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
6
Irinotecan Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 97682-44-5, 100286-90-6 60838
7
Citalopram Approved Phase 2, Phase 3 59729-33-8 2771
8
Carboplatin Approved Phase 2, Phase 3, Phase 1 41575-94-4 10339178 38904 498142
9
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 50-18-0, 6055-19-2 2907
10
Etoposide Approved Phase 2, Phase 3,Phase 1 33419-42-0 36462
11
Melphalan Approved Phase 2, Phase 3 148-82-3 460612 4053
12 Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 1 52-24-4 5453
13
Carmustine Approved, Investigational Phase 3,Phase 2,Phase 1 154-93-8 2578
14
Lomustine Approved, Investigational Phase 3,Phase 2,Phase 1 13010-47-4 3950
15
Procarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 671-16-9 4915
16
Trioxsalen Approved Phase 3,Phase 2,Phase 1 3902-71-4 5585
17
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
18
Ethanol Approved Phase 2, Phase 3,Phase 1,Early Phase 1 64-17-5 702
19
Flucytosine Approved, Investigational Phase 2, Phase 3,Phase 1 2022-85-7 3366
20
Fluorouracil Approved Phase 2, Phase 3,Phase 1 51-21-8 3385
21
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
22
Iodine Approved, Investigational Phase 3,Phase 2,Phase 1 7553-56-2 807
23
Aminolevulinic acid Approved Phase 3,Phase 2,Phase 1 106-60-5 137
24
Sunitinib Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 341031-54-7, 557795-19-4 5329102
25
Hydroxychloroquine Approved Phase 2, Phase 3,Phase 1 118-42-3 3652
26
chloroquine Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 54-05-7 2719
27
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
28
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
29
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
30
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
31
Methylphenidate Approved, Investigational Phase 3 20748-11-2, 113-45-1 4158
32
Morphine Approved, Investigational Phase 3 57-27-2 5288826
33
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
34
Copper Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 7440-50-8 27099
35
nivolumab Approved Phase 3,Phase 2,Phase 1 946414-94-4
36
Everolimus Approved Phase 2, Phase 3,Phase 1 159351-69-6 6442177
37
Sirolimus Approved, Investigational Phase 2, Phase 3,Phase 1 53123-88-9 46835353 6436030 5284616
38
Valproic Acid Approved, Investigational Phase 3,Phase 2,Phase 1 99-66-1 3121
39
Histamine Approved, Investigational Phase 3,Phase 2 51-45-6, 75614-87-8 774
40
Isotretinoin Approved Phase 3,Phase 2,Phase 1 4759-48-2 5282379 5538
41
Disulfiram Approved Phase 2, Phase 3,Phase 1,Early Phase 1 97-77-8 3117
42
Povidone Approved Phase 3 9003-39-8
43
Povidone-iodine Approved Phase 3 25655-41-8
44
Dopamine Approved Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
45
Angiotensin II Approved, Investigational Phase 3 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
46
Losartan Approved Phase 3 114798-26-4 3961
47
Meloxicam Approved, Vet_approved Phase 2, Phase 3 71125-38-7 54677470 5281106
48
Ephedrine Approved Phase 3 299-42-3 9294
49
Pseudoephedrine Approved Phase 3 90-82-4 7028
50
Norepinephrine Approved Phase 3 51-41-2 439260

Interventional clinical trials:

(show top 50) (show all 1297)

# Name Status NCT ID Phase Drugs
1 Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) Completed NCT00686725 Phase 4 Temozolomide
2 Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients Recruiting NCT02520635 Phase 4 supra-early TEMODAL® chemotherapy;standard TEMODAL® chemotherapy
3 Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI Recruiting NCT03297125 Phase 4
4 Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Terminated NCT01756729 Phase 4
5 Metronomic Temozolamide in Patients With Recurrent Glioblastoma Unknown status NCT01308632 Phase 2, Phase 3 Temozolamide, irinotecan
6 The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients Unknown status NCT02623231 Phase 2, Phase 3 Escitalopram;placebo
7 Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors Unknown status NCT00179803 Phase 2, Phase 3
8 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
9 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
10 Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme Completed NCT01450449 Phase 3
11 Chloroquine for Treatment of Glioblastoma Multiforme Completed NCT00224978 Phase 3 Chloroquine
12 The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme Completed NCT00076986 Phase 3 IL13-PE38QQR;prolifespan 20 with carmustine implant (GLIADEL® Wafer)
13 Nimotuzumab in Adults With Glioblastoma Multiforma Completed NCT00753246 Phase 3 nimotuzumab
14 Enzastaurin Versus Lomustine in Glioblastoma Completed NCT00295815 Phase 3 enzastaurin;lomustine
15 Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme Completed NCT00068952 Phase 3 Edotecarin;Temozolomide;Carmustine (BCNU);Lomustine (CCNU)
16 Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea Completed NCT00807027 Phase 3 Activated T lymphocyte(Immuncell-LC)
17 Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients Completed NCT01149109 Phase 3 Temozolomide and lomustine;Temozolomide
18 Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00482677 Phase 3 temozolomide
19 Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00006353 Phase 3 temozolomide
20 Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Completed NCT00916409 Phase 3 Temozolomide
21 Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM) Completed NCT00379470 Phase 3
22 Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status Completed NCT00689221 Phase 3 Cilengitide;Temozolomide
23 SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme Completed NCT00003293 Phase 3 leflunomide;procarbazine hydrochloride
24 Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT01364064 Phase 3 TMZ
25 Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme Completed NCT00002545 Phase 3 carmustine
26 Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma Completed NCT00777153 Phase 3 Cediranib;Cediranib;Lomustine Chemotherapy;Placebo Cediranib
27 Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma Completed NCT00154375 Phase 3 Imatinib mesylate;Hydroxyurea
28 S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma Completed NCT00017147 Phase 3 carmustine;O6-Benzylguanine
29 Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644) Completed NCT00335075 Phase 3 Temozolomide;Semustine
30 Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors Completed NCT00088400 Phase 3 TransMID
31 Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Completed NCT00884741 Phase 3 Temozolomide
32 Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma Completed NCT01480479 Phase 3 Rindopepimut (CDX-110) with GM-CSF;Temozolomide;KLH
33 A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma Completed NCT00943826 Phase 3 Bevacizumab;Temozolomide;Placebo
34 Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Completed NCT00304031 Phase 3 Concurrent temozolomide;100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle;75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
35 Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme Completed NCT00820963 Phase 3 temozolomide
36 Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly Completed NCT01502241 Phase 3 Temozolomide
37 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
38 Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma Completed NCT00003916 Phase 3
39 Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
40 High Light and Low Light Dose PDT in Glioma Completed NCT00118222 Phase 3 porfimer sodium
41 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
42 E-MOSAIC Electronic Tool to Monitor Symptoms Completed NCT00477919 Phase 3
43 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
44 Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme Recruiting NCT02685605 Phase 3 Temozolomide
45 Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Recruiting NCT02152982 Phase 2, Phase 3 Temozolomide;Veliparib
46 Phase III Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma Recruiting NCT01507506 Phase 3
47 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects Recruiting NCT03393000 Phase 3 Trans Sodium Crocetinate plus SOC
48 Disulfiram in Recurrent Glioblastoma Recruiting NCT02678975 Phase 2, Phase 3 Disulfiram;Alkylating Agents
49 Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III Recruiting NCT02761070 Phase 3 Temozolomide;Bevacizumab
50 A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification Recruiting NCT02573324 Phase 3 Temozolomide;ABT-414;Placebo for ABT-414

Search NIH Clinical Center for Glioblastoma Multiforme

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: glioblastoma

Genetic Tests for Glioblastoma Multiforme

Anatomical Context for Glioblastoma Multiforme

MalaCards organs/tissues related to Glioblastoma Multiforme:

38
Brain, T Cells, Endothelial, Bone, Testes, Bone Marrow, Prostate

Publications for Glioblastoma Multiforme

Articles related to Glioblastoma Multiforme:

(show top 50) (show all 833)
# Title Authors Year
1
Cucurbitacin B induces inhibitory effects via CIP2A/PP2A/Akt pathway in glioblastoma multiforme. ( 29393542 )
2018
2
Hyaluronic Acid-Modified Micelles Encapsulating Gem-C<sub>12</sub>and HNK for Glioblastoma Multiforme Chemotherapy. ( 29397747 )
2018
3
ATM and p53 combined analysis predicts survival in glioblastoma multiforme patients: a clinicopathologic study. ( 29369420 )
2018
4
Glioblastoma multiforme: another potential application for<sup>68</sup>Ga-PSMA PET/CT as a guide for targeted therapy. ( 29387926 )
2018
5
Stereotactic Radiosurgery in the Multimodality Management of Residual or Recurrent Glioblastoma Multiforme. ( 29393176 )
2018
6
Cell biology of glioblastoma multiforme: from basic science to diagnosis and treatment. ( 29387965 )
2018
7
Inhibition of GLO1 in Glioblastoma Multiforme Increases DNA-AGEs, Stimulates RAGE Expression, and Inhibits Brain Tumor Growth in Orthotopic Mouse Models. ( 29385725 )
2018
8
Development of an exercise intervention as part of rehabilitation in a glioblastoma multiforme survivor during irradiation treatment: a case report. ( 29382243 )
2018
9
Semantic imaging features predict disease progression and survival in glioblastoma multiforme patients. ( 29442128 )
2018
10
Management of Elderly patients with Glioblastoma - Multiforme. ( 29376741 )
2018
11
CircSMARCA5 Inhibits Migration of Glioblastoma Multiforme Cells by Regulating a Molecular Axis Involving Splicing Factors SRSF1/SRSF3/PTB. ( 29415469 )
2018
12
Early candidate biomarkers found from urine of glioblastoma multiforme rat before changes in MRI. ( 29372508 )
2018
13
Reactive Astrocytes in Glioblastoma Multiforme. ( 29363044 )
2018
14
Does radiation therapy increase gadolinium accumulation in the brain?: Quantitative analysis of T1 shortening using R1 relaxometry in glioblastoma multiforme patients. ( 29444157 )
2018
15
New aspects of glioblastoma multiforme revealed by similarities between neural and glioblastoma stem cells. ( 29383547 )
2018
16
Galectin-1 is a poor prognostic factor in patients with glioblastoma multiforme after radiotherapy. ( 29378529 )
2018
17
Comparative proteomics as a tool for identifying specific alterations within interferon response pathways in human glioblastoma multiforme cells. ( 29416731 )
2018
18
DNM3, p65 and p53 from exosomes represent potential clinical diagnosis markers for glioblastoma multiforme. ( 29449895 )
2017
19
A 4-miRNAs signature predicts survival in glioblastoma multiforme patients. ( 28869437 )
2017
20
Augmented expression of RUNX1 deregulates the global gene expression of U87 glioblastoma multiforme cells and inhibits tumor growth in mice. ( 28443460 )
2017
21
A continuous-infusion dynamic MRI model at 3.0 Tesla for the serial quantitative evaluation of microvascular proliferation in an animal model of glioblastoma multiforme. ( 28078795 )
2017
22
Advances in the targeting of HIF-1I+ and future therapeutic strategies for glioblastoma multiforme (Review). ( 27959421 )
2017
23
MiR-429 suppresses glioblastoma multiforme by targeting SOX2. ( 28749077 )
2017
24
Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome. ( 28099939 )
2017
25
MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression. ( 28187000 )
2017
26
Biomarkers and therapeutic advances in glioblastoma multiforme. ( 28840962 )
2017
27
Amplification of the EGFR gene can be maintained and modulated by variation of EGF concentrations in in vitro models of glioblastoma multiforme. ( 28934307 )
2017
28
The SGK1 Kinase Inhibitor SI113 Sensitizes Theranostic Effects of the 64CuCl2 in Human Glioblastoma Multiforme Cells. ( 28848088 )
2017
29
Upregulation of miR-181a suppresses the formation of glioblastoma stem cells by targeting the Notch2 oncogene and correlates with good prognosis in patients with glioblastoma multiforme. ( 28389242 )
2017
30
MicroRNA signatures predict prognosis of patients with glioblastoma multiforme through the Cancer Genome Atlas. ( 28938564 )
2017
31
Role of miR-223/paired box 6 signaling in temozolomide chemoresistance in glioblastoma multiforme cells. ( 28035389 )
2017
32
Natural Bioactive Compounds: Alternative Approach to the Treatment of Glioblastoma Multiforme. ( 29359162 )
2017
33
Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme. ( 28011470 )
2017
34
Valproic acid inhibits glioblastoma multiforme cell growth via paraoxonase 2 expression. ( 28108734 )
2017
35
Topotecan is a potent inhibitor of SUMOylation in glioblastoma multiforme and alters both cellular replication and metabolic programming. ( 28785061 )
2017
36
Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis. ( 28730289 )
2017
37
Lumbosacral Subdural Hematoma After Glioblastoma Multiforme Resection: Possible Radiographic Evidence for the Downward Migration of Intracranial Blood. ( 28890010 )
2017
38
Development of an integrated Monte Carlo model for glioblastoma multiforme treated with boron neutron capture therapy. ( 28765533 )
2017
39
Up-regulated microRNA-299 corrected with poor prognosis of glioblastoma multiforme patients by targeting ELL2. ( 28531325 )
2017
40
Metachronous Development of Meningothelial Meningioma, Basal Cell Carcinoma, and Glioblastoma Multiforme in a Patient with Pancreatic Incidentaloma. ( 29279708 )
2017
41
Re-irradiation for recurrent glioblastoma multiforme. ( 28841798 )
2017
42
Differentiation between progression and pseudoprogresion by arterial spin labeling MRI in patients with glioblastoma multiforme. ( 28952228 )
2017
43
Role of Intra-operative MRI (iMRI) in Improving Extent of Resection and Survival in Patients with Glioblastoma Multiforme. ( 28770902 )
2017
44
Functional differences between PD-1+ and PD-1- CD4+ effector T cells in healthy donors and patients with glioblastoma multiforme. ( 28880903 )
2017
45
Heterogeneity of tumor-infiltrating lymphocytes ascribed to local immune status rather than neoantigens by multi-omics analysis of glioblastoma multiforme. ( 28761058 )
2017
46
Primary Spinal Cord Glioblastoma Multiforme: A Rare but Uniformly Fatal Neoplasm. ( 28732416 )
2017
47
Metformin and temozolomide, a synergic option to overcome resistance in glioblastoma multiforme models. ( 29348889 )
2017
48
A Deep Learning-Based Radiomics Model for Prediction of Survival in Glioblastoma Multiforme. ( 28871110 )
2017
49
IQGAP1 in Podosomes/Invadosomes Is Involved in the Progression of Glioblastoma Multiforme Depending on the Tumor Status. ( 28098764 )
2017
50
Accelerated Hypofractionated Radiotherapy in the Era of Concurrent Temozolomide Chemotherapy in Elderly Patients with Glioblastoma Multiforme. ( 28775928 )
2017

Variations for Glioblastoma Multiforme

ClinVar genetic disease variations for Glioblastoma Multiforme:

6 (show top 50) (show all 71)
# Gene Variation Type Significance SNP ID Assembly Location
1 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121909229 GRCh38 Chromosome 10, 87933148: 87933148
2 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
3 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
4 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
5 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
6 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
7 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Pathogenic/Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
8 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
9 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
10 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
11 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
12 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
13 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
14 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
15 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
16 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
17 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
18 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
19 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
20 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
21 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
22 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic/Likely pathogenic rs113488022 GRCh37 Chromosome 7, 140453136: 140453136
23 EGFR NM_005228.4(EGFR): c.2155G> T (p.Gly719Cys) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs28929495 GRCh37 Chromosome 7, 55241707: 55241707
24 PIK3CA NM_006218.3(PIK3CA): c.1624G> A (p.Glu542Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913273 GRCh37 Chromosome 3, 178936082: 178936082
25 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913281 GRCh37 Chromosome 3, 178952084: 178952084
26 BRAF NM_004333.4(BRAF): c.1787G> T (p.Gly596Val) single nucleotide variant Pathogenic rs397507483 GRCh37 Chromosome 7, 140453148: 140453148
27 EGFR NM_005228.4(EGFR): c.2156G> C (p.Gly719Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913428 GRCh37 Chromosome 7, 55241708: 55241708
28 PIK3CA NM_006218.3(PIK3CA): c.1637A> G (p.Gln546Arg) single nucleotide variant Pathogenic/Likely pathogenic rs397517201 GRCh37 Chromosome 3, 178936095: 178936095
29 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913254 GRCh37 Chromosome 1, 115256530: 115256530
30 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587780070 GRCh37 Chromosome 17, 7578395: 7578395
31 TP53 NM_000546.5(TP53): c.580C> T (p.Leu194Phe) single nucleotide variant Pathogenic/Likely pathogenic rs587780071 GRCh37 Chromosome 17, 7578269: 7578269
32 TP53 NM_000546.5(TP53): c.659A> G (p.Tyr220Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
33 TP53 NM_000546.5(TP53): c.701A> G (p.Tyr234Cys) single nucleotide variant Pathogenic/Likely pathogenic rs587780073 GRCh37 Chromosome 17, 7577580: 7577580
34 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
35 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic/Likely pathogenic rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
36 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
37 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh38 Chromosome 2, 208248388: 208248388
38 PIK3CA NM_006218.3(PIK3CA): c.353G> A (p.Gly118Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587777790 GRCh38 Chromosome 3, 179199690: 179199690
39 MTOR NM_004958.3(MTOR): c.6644C> T (p.Ser2215Phe) single nucleotide variant Pathogenic/Likely pathogenic rs587777894 GRCh38 Chromosome 1, 11124516: 11124516
40 PIK3CA NM_006218.3(PIK3CA): c.3129G> A (p.Met1043Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913283 GRCh38 Chromosome 3, 179234286: 179234286
41 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh38 Chromosome 17, 7673778: 7673778
42 MTOR NM_004958.3(MTOR): c.4448G> T (p.Cys1483Phe) single nucleotide variant Pathogenic/Likely pathogenic rs786205165 GRCh37 Chromosome 1, 11217230: 11217230
43 PTEN NM_000314.6(PTEN): c.697C> T (p.Arg233Ter) single nucleotide variant Pathogenic rs121909219 GRCh37 Chromosome 10, 89717672: 89717672
44 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
45 TP53 NM_000546.5(TP53): c.824G> A (p.Cys275Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs863224451 GRCh38 Chromosome 17, 7673796: 7673796
46 TP53 NM_000546.5(TP53): c.584T> C (p.Ile195Thr) single nucleotide variant Pathogenic/Likely pathogenic rs760043106 GRCh38 Chromosome 17, 7674947: 7674947
47 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh37 Chromosome 3, 178936093: 178936093
48 FGFR1 NM_023110.2(FGFR1): c.1966A> G (p.Lys656Glu) single nucleotide variant Pathogenic/Likely pathogenic rs869320694 GRCh37 Chromosome 8, 38272308: 38272308
49 TP53 NM_000546.5(TP53): c.818G> C (p.Arg273Pro) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
50 TP53 NM_000546.5(TP53): c.638G> C (p.Arg213Pro) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211

Copy number variations for Glioblastoma Multiforme from CNVD:

7 (show top 50) (show all 760)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13315 1 1 117600000 Gain Glioblastoma multiforme
2 13333 1 1 124300000 Gain Glioblastoma multiforme
3 13339 1 1 124300000 Loss Glioblastoma multiforme
4 13340 1 1 124300000 Loss Glioblastoma multiforme
5 13341 1 1 124300000 Loss Glioblastoma multiforme
6 13359 1 1 12600000 Gain Glioblastoma multiforme
7 13365 1 1 16100000 Gain Glioblastoma multiforme
8 13750 1 1 27800000 Loss Glioblastoma multiforme
9 13761 1 1 28000000 Deletion Glioblastoma multiforme
10 13763 1 1 28000000 Gain Glioblastoma multiforme
11 13775 1 1 39600000 Loss Glioblastoma multiforme
12 13792 1 1 51300000 Loss Glioblastoma multiforme
13 13822 1 1 7200000 Deletion MTHFR Glioblastoma multiforme
14 14314 1 107000000 111600000 Gain Glioblastoma multiforme
15 14414 1 107915304 108309068 amplification VAV3 Glioblastoma multiforme
16 14609 1 109636509 109651136 Fusion MYBPHL Glioblastoma multiforme
17 15403 1 115061059 115084034 Fusion CSDE1 Glioblastoma multiforme
18 16435 1 124300000 247249719 Gain Glioblastoma multiforme
19 16436 1 124300000 247249719 Gain Glioblastoma multiforme
20 16437 1 124300000 247249719 Gain Glioblastoma multiforme
21 16444 1 124300000 247249719 Loss Glioblastoma multiforme
22 16683 1 130300000 212100000 Gain ATP2B4 Glioblastoma multiforme
23 19008 1 148161834 148166860 Copy number SF3B4 Glioblastoma multiforme
24 19791 1 151370387 155734861 Gain CLK2 Glioblastoma multiforme
25 20600 1 153272923 153289968 Fusion DCST1 Glioblastoma multiforme
26 20612 1 153300000 154800000 Gain RAB25 Glioblastoma multiforme
27 21114 1 156847119 156923130 Copy number SPTA1 Glioblastoma multiforme
28 22041 1 16450831 16482564 Copy number EPHA2 Glioblastoma multiforme
29 23682 1 172900000 185800000